Ztriva Eleftheria, Moschonas Iraklis C, Tselepis Alexandros, Lambrou Dimitrios, Ntaios Georgios, Savopoulos Christos, Kaiafa Georgia
First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece.
J Clin Med. 2025 May 9;14(10):3295. doi: 10.3390/jcm14103295.
: Monocyte chemotactic protein-1 (MCP-1) was implicated in the progression of atherosclerosis and is associated with elevated stroke risk. However, there is limited evidence regarding the MCP-1 role as an early biomarker for predicting the severity and outcomes of acute ischemic stroke (AIS). This prospective pilot case-control study aims to offer preliminary evidence into whether MCP-1 levels are elevated in AIS, whether they vary across different stroke subtypes, and their potential utility as a biomarker for assessing stroke severity and predicting outcomes. : MCP-1 levels were quantified using ELISA in patients with AIS or transients ischemic attack (TIA) and healthy participants. Stroke severity was assessed with the NIHSS score and functional outcome with the mRS scale. : A total of 32 patients with AIS or TIA were compared to 13 healthy controls. MCP-1 levels were found to be 77% higher in stroke patients compared to healthy controls ( < 0.001). No significant differences in MCP-1 levels were observed between patients with AIS and those with TIA, nor among different stroke subtypes. A positive correlation was observed between MCP-1 levels and NIHSS changes from admission to discharge (b = 0.376, < 0.05) and mRS scale at 6-month follow-up (b = 0.507, < 0.05). : This prospective pilot study provides preliminary evidence that MCP-1 levels are significantly elevated in AIS and are associated with NIHSS change during hospitalization and unfavorable outcome at 6-month follow-up. These findings indicate the potential of MCP-1 as an early biomarker for assessing disease severity and predicting outcomes in AIS.
单核细胞趋化蛋白-1（MCP-1）与动脉粥样硬化的进展有关，并与中风风险升高相关。然而，关于MCP-1作为预测急性缺血性中风（AIS）严重程度和预后的早期生物标志物的证据有限。这项前瞻性试点病例对照研究旨在为AIS患者中MCP-1水平是否升高、其在不同中风亚型中是否存在差异以及其作为评估中风严重程度和预测预后的生物标志物的潜在效用提供初步证据。：使用酶联免疫吸附测定（ELISA）对AIS或短暂性脑缺血发作（TIA）患者及健康参与者的MCP-1水平进行定量。用美国国立卫生研究院卒中量表（NIHSS）评估中风严重程度，用改良Rankin量表（mRS）评估功能结局。：共将32例AIS或TIA患者与13名健康对照者进行比较。发现中风患者的MCP-1水平比健康对照者高77%（<0.001）。在AIS患者与TIA患者之间以及不同中风亚型之间，未观察到MCP-1水平有显著差异。观察到MCP-1水平与入院至出院时NIHSS评分的变化（b = 0.376，<0.05）以及6个月随访时的mRS量表评分（b = 0.507，<0.05）呈正相关。：这项前瞻性试点研究提供了初步证据，表明AIS患者的MCP-1水平显著升高，且与住院期间NIHSS评分的变化以及6个月随访时的不良预后相关。这些发现表明MCP-1作为评估AIS疾病严重程度和预测预后的早期生物标志物具有潜力。
